EA200200182A1 - Способ отрицательной регуляции активности gdf-8 - Google Patents
Способ отрицательной регуляции активности gdf-8Info
- Publication number
- EA200200182A1 EA200200182A1 EA200200182A EA200200182A EA200200182A1 EA 200200182 A1 EA200200182 A1 EA 200200182A1 EA 200200182 A EA200200182 A EA 200200182A EA 200200182 A EA200200182 A EA 200200182A EA 200200182 A1 EA200200182 A1 EA 200200182A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gdf
- methods
- vaccination
- homologous
- pharmaceutical compositions
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 title abstract 10
- 108010056852 Myostatin Proteins 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 6
- 230000003828 downregulation Effects 0.000 title 1
- 238000002255 vaccination Methods 0.000 abstract 3
- 230000003053 immunization Effects 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Control Of Eletrric Generators (AREA)
- Debugging And Monitoring (AREA)
Abstract
Описаны новые способы увеличения мышечной массы путем иммунизации животных против фактора дифференцировки роста 8 (GDF-8, миостатин). Иммунизацию предпочтительно осуществляют путем введения аналогов GDF-8, способных индуцировать вырабатывание антител против гомологичного GDF-8. Особенно предпочтительным иммуногеном является гомологичный GDF-8, который был модифицирован путем введения одного или нескольких чужеродных иммунодоминантных и смешанных Т-клеточных эпитопов, которые, в основном, сохраняют третичную структуру гомологичного GDF-8. Описана также вакцинация нуклеиновыми кислотами против GDF-8 и вакцинация с использованием живых вакцин, а также способы и средства осуществления такой вакцинации. Такими способами и средствами являются способы идентификации эффективных иммуногенных аналогов GDF-8, способы получения аналогов и фармацевтических композиций, а также фрагменты нуклеиновых кислот, векторы, трансформированные клетки, полипептиды и фармацевтические композиции.Отчет о международном поиске был опубликован 2001.07.19.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901014 | 1999-07-20 | ||
| US14527599P | 1999-07-26 | 1999-07-26 | |
| PCT/DK2000/000413 WO2001005820A2 (en) | 1999-07-20 | 2000-07-20 | Method for down-regulating gdf-8 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200200182A1 true EA200200182A1 (ru) | 2002-06-27 |
| EA005248B1 EA005248B1 (ru) | 2004-12-30 |
Family
ID=26065065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200200182A EA005248B1 (ru) | 1999-07-20 | 2000-07-20 | Способ отрицательной регуляции активности gdf-8 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7056512B1 (ru) |
| EP (1) | EP1200119A2 (ru) |
| JP (1) | JP2003506325A (ru) |
| KR (1) | KR100750695B1 (ru) |
| CN (1) | CN1384757A (ru) |
| AU (1) | AU778470B2 (ru) |
| CA (1) | CA2379852A1 (ru) |
| EA (1) | EA005248B1 (ru) |
| EE (1) | EE200200025A (ru) |
| HK (1) | HK1048937A1 (ru) |
| HR (1) | HRP20010900A2 (ru) |
| HU (1) | HUP0201861A3 (ru) |
| IL (1) | IL146845A0 (ru) |
| MX (1) | MXPA01013232A (ru) |
| NO (1) | NO20016252L (ru) |
| NZ (1) | NZ517058A (ru) |
| PL (1) | PL353855A1 (ru) |
| SK (1) | SK722002A3 (ru) |
| TR (2) | TR200200133T2 (ru) |
| WO (1) | WO2001005820A2 (ru) |
| ZA (1) | ZA200109901B (ru) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| WO1999056768A1 (en) * | 1998-05-06 | 1999-11-11 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
| US7037501B2 (en) | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| WO2004019975A2 (en) * | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US7511012B2 (en) * | 2002-12-20 | 2009-03-31 | Amgen Inc. | Myostatin binding agents |
| UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| ITMI20071072A1 (it) | 2007-05-25 | 2008-11-26 | Lps Electronics S R L | Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa. |
| KR20060120229A (ko) * | 2003-12-31 | 2006-11-24 | 쉐링-프라우 리미티드 | 중화 에피토프계 성장 증진 백신 |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| CA2582940A1 (en) | 2004-09-30 | 2006-04-06 | Orico Limited | Myostatin isoform |
| CN101379086B (zh) | 2005-08-19 | 2013-07-17 | 惠氏公司 | 抗gdf-8的拮抗剂抗体以及在als和其他gdf-8-相关病症治疗中的用途 |
| CN100450545C (zh) * | 2006-08-03 | 2009-01-14 | 中国医学科学院基础医学研究所 | 肌肉生长抑制素在制备抗肿瘤药物中的应用 |
| AU2007279456A1 (en) | 2006-08-03 | 2008-02-07 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| JP2010535708A (ja) | 2007-08-03 | 2010-11-25 | ビオマリン アイジーエー リミテッド | デュシェンヌ型筋ジストロフィーの治療のための薬物併用 |
| KR100857861B1 (ko) * | 2007-10-15 | 2008-09-11 | 주식회사 바이오리더스 | Ｍｙｏ－２ 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| WO2013003983A1 (zh) * | 2011-07-06 | 2013-01-10 | 湖北省农业科学院畜牧兽医研究所 | 猪肌抑素基因座位及其应用 |
| PT2780368T (pt) | 2011-11-14 | 2018-03-22 | Regeneron Pharma | Composições e métodos para aumentar a massa muscular e a força muscular antagonizando especificamente gdf8 e/ou activina a |
| JP6433889B2 (ja) | 2012-06-15 | 2018-12-05 | ファイザー・インク | Ｇｄｆ−８に対する改善された拮抗抗体およびその使用 |
| PT2880053T (pt) | 2012-08-01 | 2020-05-22 | Ikaika Therapeutics Llc | Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4 |
| LT2981822T (lt) | 2013-05-06 | 2020-12-28 | Scholar Rock, Inc. | Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| EP2960653A1 (en) * | 2014-06-24 | 2015-12-30 | Stichting Kwaliteitsgarantie Vleeskalversector | Diagnostic kit and method for the identification of the manipulation of muscle mass in a domestic animal |
| WO2016168613A1 (en) | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| US11248044B2 (en) | 2018-03-01 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor |
| EP3897689A1 (en) | 2018-12-21 | 2021-10-27 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン，インコーポレイティド | 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変 |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| PL194221B1 (pl) | 1997-04-15 | 2007-05-31 | Pharmexa As | Zmodyfikowana cząsteczka ludzkiego TNFalfa, dimery, oligomery lub multimery zmodyfikowanej cząsteczki ludzkiego TNFalfa, wyizolowana cząsteczka DNA, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania zmodyfikowanej cząsteczki ludzkiego TNFalfa, szczepionki przeciwko TNFalfa oraz zastosowanie przynajmniej jednej zmodyfikowanej cząsteczki ludzkiego TNFalfa |
| DE69841139D1 (de) * | 1997-07-14 | 2009-10-22 | Univ Liege | Mutationen im myostatingen steigern muskelmasse in säugetieren |
| EP1038016A2 (en) * | 1997-12-16 | 2000-09-27 | Valentis Inc. | Needle-free injection of formulated nucleic acid molecules |
| GB2333706A (en) * | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
-
2000
- 2000-07-20 EA EA200200182A patent/EA005248B1/ru not_active IP Right Cessation
- 2000-07-20 CN CN00810614A patent/CN1384757A/zh active Pending
- 2000-07-20 US US09/620,586 patent/US7056512B1/en not_active Expired - Fee Related
- 2000-07-20 EE EEP200200025A patent/EE200200025A/xx unknown
- 2000-07-20 IL IL14684500A patent/IL146845A0/xx unknown
- 2000-07-20 HU HU0201861A patent/HUP0201861A3/hu unknown
- 2000-07-20 TR TR2002/00133T patent/TR200200133T2/xx unknown
- 2000-07-20 CA CA002379852A patent/CA2379852A1/en not_active Abandoned
- 2000-07-20 PL PL00353855A patent/PL353855A1/xx unknown
- 2000-07-20 EP EP00945671A patent/EP1200119A2/en not_active Withdrawn
- 2000-07-20 JP JP2001511477A patent/JP2003506325A/ja active Pending
- 2000-07-20 AU AU59675/00A patent/AU778470B2/en not_active Ceased
- 2000-07-20 NZ NZ517058A patent/NZ517058A/en unknown
- 2000-07-20 US US10/031,342 patent/US7070784B1/en not_active Expired - Fee Related
- 2000-07-20 WO PCT/DK2000/000413 patent/WO2001005820A2/en active IP Right Grant
- 2000-07-20 SK SK72-2002A patent/SK722002A3/sk unknown
- 2000-07-20 KR KR1020027000866A patent/KR100750695B1/ko not_active IP Right Cessation
- 2000-07-20 TR TR2004/00621T patent/TR200400621T2/xx unknown
- 2000-07-20 MX MXPA01013232A patent/MXPA01013232A/es active IP Right Grant
-
2001
- 2001-11-30 ZA ZA200109901A patent/ZA200109901B/xx unknown
- 2001-12-04 HR HR20010900A patent/HRP20010900A2/hr not_active Application Discontinuation
- 2001-12-19 NO NO20016252A patent/NO20016252L/no not_active Application Discontinuation
-
2003
- 2003-02-17 HK HK03101114.6A patent/HK1048937A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EE200200025A (et) | 2003-04-15 |
| KR100750695B1 (ko) | 2007-08-22 |
| TR200200133T2 (tr) | 2002-05-21 |
| NZ517058A (en) | 2004-04-30 |
| HUP0201861A3 (en) | 2004-07-28 |
| HRP20010900A2 (en) | 2003-08-31 |
| NO20016252L (no) | 2002-03-15 |
| JP2003506325A (ja) | 2003-02-18 |
| TR200400621T2 (tr) | 2004-08-23 |
| SK722002A3 (en) | 2003-02-04 |
| CN1384757A (zh) | 2002-12-11 |
| US7070784B1 (en) | 2006-07-04 |
| AU778470B2 (en) | 2004-12-09 |
| MXPA01013232A (es) | 2005-05-24 |
| HK1048937A1 (zh) | 2003-04-25 |
| ZA200109901B (en) | 2003-05-28 |
| US7056512B1 (en) | 2006-06-06 |
| NO20016252D0 (no) | 2001-12-19 |
| AU5967500A (en) | 2001-02-05 |
| CA2379852A1 (en) | 2001-01-25 |
| EP1200119A2 (en) | 2002-05-02 |
| WO2001005820A2 (en) | 2001-01-25 |
| EA005248B1 (ru) | 2004-12-30 |
| IL146845A0 (en) | 2002-07-25 |
| WO2001005820A3 (en) | 2001-07-19 |
| PL353855A1 (en) | 2003-12-01 |
| KR20020026544A (ko) | 2002-04-10 |
| HUP0201861A2 (en) | 2002-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200200182A1 (ru) | Способ отрицательной регуляции активности gdf-8 | |
| EA200200889A1 (ru) | Новый способ супресии амилоида | |
| EA200400332A1 (ru) | Новый способ понижающей регуляции амилоида | |
| MXPA02007796A (es) | Metodo novedoso para la disminucion de cuerpos amiloides. | |
| RU2422460C2 (ru) | Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного | |
| JP3328644B2 (ja) | 病原性ボレリア・ブルグドルフェリ菌株、病原性ボレリア・ブルグドルフェリの単離及び再培養法 | |
| EA200100425A1 (ru) | Новые способы терапевтической вакцинации | |
| RU2008102930A (ru) | Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки | |
| CN1222936A (zh) | 包含疟原虫msp－1的c－末端片段的重组蛋白 | |
| NO20051779L (no) | Immunisering mot autologt ghrelin | |
| CN86100979A (zh) | 疟疾疫苗的制备方法 | |
| AU663863B2 (en) | Nematode vaccine | |
| NO20040431L (no) | Ny fremgangsmate for nedregulering av amyloid | |
| Wiesmüller et al. | The antibody response in BALB/c mice to the Plasmodium falciparum circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant. | |
| WO1988002757A1 (en) | Hybrid proteins or polypeptides | |
| US20120128706A1 (en) | Immune adjuvant comprising atp | |
| CN1053642A (zh) | 传染性支气管炎病毒疫苗 | |
| YU87201A (sh) | Postupak za nishodnu regulaciju gdf-8 aktivnosti | |
| RU2004103468A (ru) | Нуклеиновые кислоты, кодирующие рекомбинантный 250 к-да-антиген спорозоитов/мерозоитов eimeria maxima, и их применения | |
| ECSP003580A (es) | Metodos nuevos para aumentar la masa muscular mediante la inmunizacion contra el gdf-8 | |
| EA200500480A1 (ru) | Иммунизация против аутологичного грелина | |
| US20090252751A1 (en) | Immune adjuvant comprising ubiquinone | |
| BR102016010178A2 (pt) | Chemical products with potential use as antigenic diagnostic markers and / or recombinant vaccines against toxoplasmose formed through the junction of bet epitopes of ama-1, gra-7 and sag-1 proteins of toxoplasma gondii | |
| WO1998018821A1 (en) | Vaccines against pathogens characterized by serological cross-reaction but lacking cross-protection | |
| JP2002179700A (ja) | イヌ卵透明帯ｃｚｐａタンパクのアミノ末端から＃５０−６７のアミノ酸配列を有する合成ペプチドによる避妊ワクチン。 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |